AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Primary Biliary Cirrhosis Pipeline Review, H1 2019 - ResearchAndMarkets.com

May 22, 2019

DUBLIN--(BUSINESS WIRE)--May 22, 2019--

The “Primary Biliary Cirrhosis - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Primary Biliary Cirrhosis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 2, 11, 3, 1, 2 and 1 respectively.

Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)

Companies Mentioned

  • Albireo Pharma Inc
  • Allergan Plc
  • Arena Pharmaceuticals Inc
  • Biocad
  • Cadila Healthcare Ltd
  • CymaBay Therapeutics Inc
  • Dr. Falk Pharma GmbH
  • Eli Lilly and Co
  • Enanta Pharmaceuticals Inc
  • Genfit SA
  • GenKyoTex SA
  • Gilead Sciences Inc
  • Kowa Co Ltd
  • NGM Biopharmaceuticals Inc
  • Novartis AG
  • Tiziana Life Sciences Plc
  • Virobay Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/gndih8

View source version on businesswire.com:https://www.businesswire.com/news/home/20190522005695/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Liver and Kidney Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/22/2019 12:56 PM/DISC: 05/22/2019 12:56 PM

http://www.businesswire.com/news/home/20190522005695/en

All contents © copyright 2019 The Associated Press.All rights reserved.